David Platt insider trades: Bioxytran (BIXT) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where David reports to the SEC
Open-market buys and sales
19 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Aug 15, 2024 | BIXT | ↑ Buy | 1,592,921 | $0.12 | $198K | by NDPD Pharma | Aug 20, 2024 (5d) |
| May 15, 2015 | BTHE | ↑ Buy | 6,000 | $0.12 | $748 | Direct | May 18, 2015 (3d) |
| Mar 9, 2015 | BTHE | ↑ Buy | 10,000 | $0.22 | $2K | Direct | Mar 10, 2015 (1d) |
| Feb 17, 2015 | BTHE | ↑ Buy | 250 | $0.58 | $145 | Direct | Feb 19, 2015 (2d) |
| Feb 12, 2015 | BTHE | ↑ Buy | 250 | $0.51 | $128 | Direct | Feb 13, 2015 (1d) |
| Feb 4, 2015 | BTHE | ↑ Buy | 600 | $0.43 | $260 | Direct | Feb 4, 2015 (0d) |
| Jan 28, 2015 | BTHE | ↑ Buy | 800 | $0.45 | $360 | Direct | Jan 29, 2015 (1d) |
| Jan 23, 2015 | BTHE | ↑ Buy | 500 | $0.40 | $200 | Direct | Jan 27, 2015 (4d) |
| Jan 20, 2015 | BTHE | ↑ Buy | 3,000 | $0.34 | $1K | Direct | Jan 23, 2015 (3d) |
| Jan 16, 2015 | BTHE | ↑ Buy | 1,000 | $0.60 | $600 | Direct | Jan 16, 2015 (0d) |
| Jan 12, 2015 | BTHE | ↑ Buy | 1,500 | $0.63 | $939 | Direct | Jan 12, 2015 (0d) |
| Jan 8, 2015 | BTHE | ↑ Buy | 700 | $0.65 | $455 | Direct | Jan 8, 2015 (0d) |
| Jan 5, 2015 | BTHE | ↑ Buy | 100 | $0.60 | $60 | Direct | Jan 7, 2015 (2d) |
| Jan 2, 2015 | BTHE | ↑ Buy | 1,100 | $0.65 | $713 | Direct | Jan 5, 2015 (3d) |
| Dec 31, 2014 | BTHE | ↑ Buy | 3,000 | $0.64 | $2K | Direct | Dec 31, 2014 (0d) |
| Jun 11, 2012 | BTHE | ↑ Buy | 1,985 | $0.89 | $2K | Direct | Jun 12, 2012 (1d) |
| Mar 20, 2012 | BTHE | ↓ Sell | 160,000 | $0.25 | $40K | Direct | Mar 26, 2012 (6d) |
| Sep 18, 2008 | PRW | ↑ Buy | 1,000 | $0.23 | $230 | Direct | Sep 22, 2008 (4d) |
| Jun 8, 2006 | PRW | ↓ Sell | 4,400 | $3.75 | $17K | Direct | Jun 12, 2006 (4d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other BIXT insiders
Open-market trades in the last 12 months
About David Platt's insider trades
David Platt is CEO at Bioxytran (BIXT). Since Jun 8, 2006, David has reported 17 open-market purchases worth $209K and 2 sales worth $57K on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (11 filings), gifts (7 filings), other transactions (3 filings), conversions (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every BIXT insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.